B C Gohlke1, H Fahnenstich, C Dame, N Albers. 1. Department of Paediatrics, University of Bonn, Adenauerallee 119, DE-53113 Bonn, Germany. Gohlke-Bonn@t-online.de
Abstract
OBJECTIVE: An increasing body of evidence supports a major role for the insulin-like growth factors (IGFs) in the control of human fetal growth. Individual data at various times of pregnancy suggest that IGF-I and IGF-II levels remain stable up to the 33rd week of pregnancy. Thereafter, both increase to reach values 2-3 times higher at term. In order to provide an accurate reflection of fetal IGFs in utero, we sampled fetal blood from the umbilical cord by cordocentesis. METHODS: We measured IGF-I and IGF-II in 12 fetuses longitudinally for up to 5 times between the 21st week of gestation and delivery. RESULTS: All patients showed a progressive increase in IGF-I and IGF-II levels. Data determined during different time intervals (before 29th, 29th to 32nd, after 32nd week) were compared and the main increase was found after the 32nd week. The median for IGF-I before the 29th week was 33.5 ng/ml (range 19-40.5) and increased to 41 ng/ml (32-59) between the 29th to 32nd and further to 54.1 ng/ml (range 17-70) thereafter. During the same time interval, the median for IGF-II increased from 217 ng/ml (86-326) to 349 ng/ml (227-467). In 7 patients, cord blood after delivery was available. For IGF-II a further increase was consistently found after birth (from 282 ng/ml (175-511) to 393 ng/ml (297-513)), whereas only 2 fetuses showed an increase in IGF-I. CONCLUSION: We conclude that in human fetuses, IGF-I and IGF-II levels increase longitudinally throughout pregnancy. Therefore, they may become important markers of healthy fetal development. Copyright 2004 S. Karger AG, Basel
OBJECTIVE: An increasing body of evidence supports a major role for the insulin-like growth factors (IGFs) in the control of human fetal growth. Individual data at various times of pregnancy suggest that IGF-I and IGF-II levels remain stable up to the 33rd week of pregnancy. Thereafter, both increase to reach values 2-3 times higher at term. In order to provide an accurate reflection of fetal IGFs in utero, we sampled fetal blood from the umbilical cord by cordocentesis. METHODS: We measured IGF-I and IGF-II in 12 fetuses longitudinally for up to 5 times between the 21st week of gestation and delivery. RESULTS: All patients showed a progressive increase in IGF-I and IGF-II levels. Data determined during different time intervals (before 29th, 29th to 32nd, after 32nd week) were compared and the main increase was found after the 32nd week. The median for IGF-I before the 29th week was 33.5 ng/ml (range 19-40.5) and increased to 41 ng/ml (32-59) between the 29th to 32nd and further to 54.1 ng/ml (range 17-70) thereafter. During the same time interval, the median for IGF-II increased from 217 ng/ml (86-326) to 349 ng/ml (227-467). In 7 patients, cord blood after delivery was available. For IGF-II a further increase was consistently found after birth (from 282 ng/ml (175-511) to 393 ng/ml (297-513)), whereas only 2 fetuses showed an increase in IGF-I. CONCLUSION: We conclude that in human fetuses, IGF-I and IGF-II levels increase longitudinally throughout pregnancy. Therefore, they may become important markers of healthy fetal development. Copyright 2004 S. Karger AG, Basel
Authors: Tanya Agurs-Collins; Sabine Rohrmann; Catherine Sutcliffe; Jessica L Bienstock; Deborah Monsegue; Folasade Akereyeni; Gary Bradwin; Nader Rifai; Michael N Pollak; Elizabeth A Platz Journal: Cancer Causes Control Date: 2012-01-18 Impact factor: 2.506
Authors: Zofia N Zysman-Colman; Marissa J Kilberg; Victor S Harrison; Alessandra Chesi; Struan F A Grant; Jonathan Mitchell; Saba Sheikh; Denis Hadjiliadis; Michael R Rickels; Ronald C Rubenstein; Andrea Kelly Journal: Pediatr Res Date: 2020-05-09 Impact factor: 3.756
Authors: Ionel Sandovici; Aikaterini Georgopoulou; Vicente Pérez-García; Antonia Hufnagel; Jorge López-Tello; Brian Y H Lam; Samira N Schiefer; Chelsea Gaudreau; Fátima Santos; Katharina Hoelle; Giles S H Yeo; Keith Burling; Moritz Reiterer; Abigail L Fowden; Graham J Burton; Cristina M Branco; Amanda N Sferruzzi-Perri; Miguel Constância Journal: Dev Cell Date: 2021-12-27 Impact factor: 12.270